Objective: The present study was designed to evaluate clinical practice of cardiovascular (CV) risk management and the influence of follow-up on risk profile among hypertensive patients.
The designation of added risk in the European Society of Hypertension-European Society of Cardiology guidelines takes into account not only blood pressure (BP), but also recently identified risk factors (such as C-reactive protein) and measures of renal function, as well as CVD risk factors with established adverse effects on morbidity and mortality. [4] In Turkey, the Total Cardiovascular Risk Management Initiative, a collaborative effort of the Ministry of Health and the Turkish Societies of Cardiology, Internal Medicine, Neurology, Endocrinology and Metabolism, and Hypertension and Renal Diseases was put into practice. While the program was modified to accommodate circumstances specific to Turkey, risk scoring is based on the model of the Joint British Societies, published in 2005. [8] Patients with established CVD are among those at highest risk, and the larger the risk burden, the more important are the achievement and maintenance of target BP. [7] However, in spite of tremendous progress in medical treatment, and in the understanding and management of hypertension, [3] fewer than two-thirds of patients with hypertension have BP under control. [2] Although the goal should be a restoration to optimal levels of the various components of CV risk in order to improve CV health, [9] detailed data regarding management of CV risk factors in clinical or office settings are scarce. While various CV risk factor guidelines have been published, [6, 10] their dissemination and implementation have been neither especially successful nor well-studied. [11] Long-term trends in hypertension research and treatment have shifted toward earlier detection and aggressive treatment, with an emphasis on prevention, while questions regarding the precise nature of hypertension, and the optimal modes of treatment and risk assessment still challenge investigators. [3] Clinical practice of physicians working in CV risk management at internal medicine and cardiology clinics is associated with the development of risk models leading to increased awareness of risk management and the support of approaches such as the domestic initiative.
The present non-interventional, observational study was designed to assess clinical practice in CV risk management and related patient compliance within the past 12 months. Presented elsewhere, the crosssectional phase of the study was conducted at 50 centers across Turkey, and included 1023 patients with essential hypertension. [12] The results of 9-month followup in the longitudinal phase subgroup are presented, and address clinical practice in CV risk management, patient compliance, and the influence of the follow-up period on CVD risk profiles of Turkish hypertensive patients.
METHODS

Study population
The cross-sectional phase of the present study was designed to evaluate clinical practice of CV risk management in hypertensive patients at internal medicine and cardiology clinics. Conducted at 50 centers across Turkey, 1023 essential hypertensive patients were included. Criteria were age ≥18 years, previous diagnosis of "essential hypertension," administration of single or combined antihypertensive therapy, and previous (<3 months) laboratory evaluations (including electrocardiography, urine analysis, and blood glucose, renal function, and microalbuminuria testing). Main exclusion criteria were known or suspected diagnosis of secondary hypertension, current hospitalization or appointment for hospitalization during study duration, and enrollment in external study.
In the cross-sectional phase, CV risk was determined, and patients were stratified according to risk level (low risk, medium risk, high risk, and very high risk). [12] High-and very high-risk patients, and those >75 years of age were invited to participate in the longitudinal follow-up phase. Change in CV risk status and patient compliance with CV risk management recommendations were recorded in a subgroup of patients (n=397) who had attended at least 1 follow-up visit within 9 months (mean [SD] = 7.7 [3.0] months).
The study was conducted according to the International Conference on Harmonisation Good Clinical Practice guidelines and local regulations. Approval of the ethics committee was obtained prior to commencement, and informed consent was obtained prior to enrollment. According to the real-time, observa-tional, and non-interventional design of the study, treatment decisions were left to the discretion of the physician, including those regarding alternative or additive treatment of patients with BP not controlled by current medication.
CVD risk classification
Classification of patients with low, moderate, high, or very high risk was based on age, serum low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, BP, presence of diabetes mellitus, and smoking habits, with scoring charts prepared by the Turkish Society of Cardiology (http://www.tkd. org.tr/menu/213/) according to Framingham study results. [13] Outcome variables Recorded at enrollment were patient demographic data including age, gender, physical measurements (height, weight, body mass index, and waist circumference), and medical history (duration of hypertension, concomitant diseases, and risk factors).
In order to assess modifications in CV risk from baseline, data regarding systolic and diastolic blood pressure, serum LDL and HDL cholesterol, history and/or laboratory tests related to diabetes mellitus, and smoking status were collected at every visit. Practice patterns regarding CV risk management included physician recommendations related to hypertension, dyslipidemia, diabetes mellitus, smoking status, and obesity. Past practice patterns (both those of 12 months prior to enrollment and those between initial and previous follow-up visit), and current patterns (of initial and previous follow-up visits) were assessed, as was patient compliance.
Statistical analysis
It was estimated that the study population should comprise a minimum of 1050 patients in order to determine risk management of 1-50% of patients, with a 95% confidence interval and 3% rate of error. Data were collected twice, the first set included the data of 1023 patients enrolled in the cross-sectional phase of the study, [12] and the second included the data of 397 patients who attended at least 1 follow-up visit within 9 months of enrollment (longitudinal phase). Findings collected at the initial and final follow-up visit of the longitudinal phase subgroup (n=397) are presented.
Statistical analyses were performed using SPSS for Windows (version 12.0; SPSS Inc., Chicago, IL, USA). Descriptive statistical parameters for numerical variables (mean, median, SD, minimum, and maximum) and frequencies for categorical variables were calculated. Comparison of categorical variables was performed using the chi-square test, while paired Student's t-test, Mann-Whitney U test, Kruskal-Wallis test, and two-sample proportion tests were used for numerical data. A p value <0.05 was considered statistically significant. Data are expressed as mean (SD) and number (n; %) where appropriate.
RESULTS
Baseline characteristics
A total of 397 patients (mean [SD] age: 59.2 [11.5] years; 62.5% females) were included. Duration of hypertension was 8.3 (7.0) years (Table 1) . Physical parameters (weight, height, body mass index, and waist circumference) are also presented in Table 1 . Of the CVD risk factors, metabolic syndrome was present in 59.1%, family history in 41.7%, diabetes mellitus in 41.1%, left ventricle hypertrophy in 29.5%, coronary heart disease (CHD) in 24.1%, obesity in 22.4%, microalbuminuria in 13.5%, renal disease in 3.1%, and peripheral arterial disease in 2.6% of patients at enrollment visit (Table 1) .
CV risk management history
Despite having been diagnosed with essential hypertension, the BP of 6% of patients had not been measured in 12 months. Of those whose BP had been measured, the level of 86.6% was high ( Table 2) . Taking histories and current management of CV risk into consideration, patients in certain subgroups were found to have been evaluated with recommendation of appropriate treatment for risk factors (including dyslipidemia, diabetes mellitus, obesity, and smoking) ( Table 2) .
Ongoing antihypertensive treatment consisted of diuretics (n=176, 44.3%), beta-blockers (n=113, 28.5%), angiotensin-receptor blockers (ARBs; n=167, 42.1%), angiotensin-converting-enzyme inhibitors (ACE-Is; n=91, 22.9%), calcium-channel blockers (CCBs; n=100, 25.2%), alpha blockers (n=11, 2.8%), and aldosterone antagonists (n=11, 2.8%).
CV risk management at study centers and patient compliance
At enrollment visit, new antihypertensive medications with quitting smoking (21.1%) and drug treatment for obesity (9.7%) ( Table 3) .
At the final visit, nearly every patient (97.7%) was on antihypertensive medication, including diuretics (n=227, 57.2%), beta-blockers (n=156, 39.3%), ARBs (n=237, 60.0%), ACE-Is (n=101, 25.4%), CCBs (n=158, 40%), alpha blockers (n=18, 4.5%), and aldosterone antagonists (n=13, 3.3%).
Further drug and dietary recommendations were made (Table 3) , and new antihypertensive medications were prescribed for 19.3% of patients, including diuretics (n=25, 6.3%), betablockers (n=21, 5.3%), ARBs (n=20, 5.0%), ACE-Is (n=17, 4.3%), CCBs (n=22, 5.5%), and alpha blockers (n=4, 1%).
Ten-year CHD risk
Mean (SD) 10-year CHD risk was calculated as 25.7% (12.9) in males and 16.4% (8.8) in females at enrollment visit (Table 4 ). There was a significant decrease in the mean (SD) 10-year CHD risk in both genders (p<0.001) within 9 months (Table 4) . Factors used to calculate 10-year CHD risk at both visits for both genders are presented in Table 4 . Among these, significant reductions in systolic and diastolic blood pressures and LDL cholesterol seemed to contribute to the decrease in risk.
Risk classification
Patients were classified as having very high (19.6%), high (20.7%), moderate (38.3%), and were prescribed for 68.5% of patients as follows: diuretics (n=120, 30.2%), beta-blockers (n=57, 14.4%), ARBs (n=117, 29.5%), ACE-Is (n=60, 15.1%), CCBs (n=114, 28.7%), alpha blockers (n=11, 2.8%), and aldosterone antagonists (n=4.1%).
Drug and dietary treatments, respectively, were recommended at enrollment visit for hypertension in 90.4% and 88.2% of patients, for dyslipidemia in 48.9% and 62.0% of patients, for diabetes in 29.2% and 36.5% of patients, and for obesity in 3.8% and 55.4% of patients (Table 3) .
At final follow-up, patient compliance with enrollment-visit recommendations was assessed by questionnaire. The highest compliance was observed with antihypertensive medications (94.7%), the poorest low (21.4%) added risk for CVD at enrollment visit, while only 6.6% had very high and 13.4% had high risk at follow-up evaluation (p<0.001 vs enrollment for both; Table 5 ). The distribution at both visits of patients according to diabetes mellitus, metabolic syndrome, renal disease or microalbuminuria, and obesity are presented in Table 5 . The shift toward lower risk grouping was more prominent in patients with diabetes, metabolic syndrome, and in those who were obese (Table 5) .
Of the 78 patients in the very high risk category at enrollment, 22 (28.2%) remained classified as such at follow-up, and improvement was similar among patients in other categories (Table 5) .
When assessed at the individual level, no change in risk status was observed during follow-up in 207 patients (52.1%), a decrease was observed in 170 patients (42.8%), and an increase was observed in 20 patients (5.0%). In patients with a positive shift or no change, significant reductions in systolic and diastolic blood pressure (p<0.001 for each), and a decrease in of patients, target BP was not reached at enrollment or follow-up, while 53.7% of patients who did not achieve target BP at enrollment had reached their targets at follow-up (Table 7) .
DISCUSSION
Based on data of the TEKHARF study [14] in the 1990s and the PatenT study [15] conducted in 2003, preva-LDL cholesterol (p<0.001 and 0.003, respectively) were evident. A significant increase (p=0.007) in HDL cholesterol was observed in the former group, but not in the latter (Table 6 ).
Achievement of target BP
The percentage of patients who had achieved target BP was estimated to have increased from 18.9% at enrollment to 69.8% at follow-up (p<0.001). In 27.5% emphasizes the need for insight into the clinical practice and efficacy of current treatment trends of CV risk management in Turkish hypertensive patients. As has been consistently reported, hypertension is not a mere function of a discrete BP level, but should be considered part of a complex syndrome of pathologic changes in vasculature and target organs. [3] Accordingly, metabolic syndrome, family history, diabetes mellitus, left ventricular hypertrophy, coronary heart disease, obesity, microalbuminuria, renal lence of hypertension in Turkey was approximately 30%. However, given that, according to the PatenT study, 32.2% of participants had never had their BP measured, only 40.7% of hypertension patients were aware of their diagnosis, 31.1% were receiving pharmacological treatment, and only 8.1% had BP under control, [15] it seems reasonable to expect a high CV risk in relation to poor management. Identification of high and very high levels of risk at the initial visit of approximately 40% of patients in the present study unsatisfactory in the United States, Canada, and in European countries, [17] with only an approximate third of hypertensive patients reaching recommended goals. [3] Initially diagnosed in the fifth decade of life and lasting an average of 8 years, systolic and diastolic blood pressure values recorded at enrollment indicated insufficient BP control, independent of risk stratification. Only 18.9% of patients met target BP levels according to risk groups. disease, and peripheral arterial disease were the established risk factors encountered, in decreasing order, in the present study population, which included patients who had suffered from essential hypertension for fewer than 10 years.
In spite of major advances in pharmacological treatment, hypertension is an increasingly common health problem worldwide. [16] BP control in patients on antihypertensive medication has been evaluated as Problems with patient compliance are reportedly the leading cause of poor BP control. [20] Less than a third of patients were reported to have adhered to antihypertensive drug treatment 1 year after initial prescription, and change or discontinuation of treatment was documented in 40-50% of patients within 6 months. [21] Although frequency of antihypertensive prescription was in line with the significant increase in use demonstrated by NHANES data, [2] BP control of the present study population seemed to reflect not only high patient compliance but also the aim of the increase in prescription, to lower high levels. [2] To this end, diuretics, ARBs, CCBs, and beta-blockers were the most commonly prescribed antihypertensive medications. In the present study, patient compliance with medical treatment aimed at CV risk management for hypertension, dyslipidemia, and diabetes mellitus was higher than that corresponding to dietary recommendations.
Without exception, current guidelines acknowledge that in most patients, ≥1 antihypertensive agent is required to reach BP goals, particularly that of <130/80 mmHg, which newer guidelines encourage, as part of an effective strategy for reducing CV risk. [22] Identification of diuretics and ARBs as the new and continuing medications most commonly prescribed during the period of the present study is in accordance with several lines of evidence, including recent updates to the guidelines of the European Society of Hypertension and the European Society of Cardiology, [5] and a recent analysis supporting the use of ACE-Is, ARBs, CCBs, or thiazide diuretics as a firststep therapy, to be supplemented with other antihypertensive drugs if necessary. [23] Given the favorable tolerability profile of ARBs, with better adherence and persistence making them ideal candidates for combination therapy, [24] similarly increased prescription rates for ARBs and diuretics in the present population are noteworthy.
Absence of alteration in risk status during followup in half the present population is similarly noteworthy, as significant improvement in high BP and dyslipidemia was obtained only in patients with a decrease in risk level during follow-up. Regarding the likelihood of better management in longer-term follow-up, achievement of risk reduction with significant improvement in control of hypertension and dyslipidIn 9 months of follow-up, an average of 20-25 mmHg reduction in systolic and diastolic blood pressure levels occurred in patients of both genders, and 70.8% reached target BP set according to risk group. Accounting for this successful rate of BP control, more than 97% of patients were under hypertensive treatment at final follow-up, and more importantly, patient compliance with antihypertensive medication was quite satisfactory, reaching 95%. In addition, 10-year CV risk estimates, and significant decline in percentage of patients in high-and very high-risk groups seem to indicate the selection of effective risk management strategies during the 9-month follow-up period.
Along with the reduction in high-and very highrisk patients with concomitant diabetes or metabolic syndrome, findings of the present study demonstrate that achievement of target BP and improvement in dyslipidemia were evident in a higher number of patients at the final visit, compared to the first. Regarding effective control of systolic and diastolic blood pressure and dyslipidemia during follow-up, 10-year CVD risk was significantly lower at the final visit for patients of each gender.
Regardless of progressive increases in dosage of multiple medications, controlling elevated BP of patients who are gaining weight, performing little physical activity, smoking, and drinking alcohol in excess is difficult. [18] As defined in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) [6] and the World Health Organization and International Society of Hypertension (WHO/ISH) [7] guidelines, major lifestyle modifications are often critical in the control of underlying hypertension. [18] The role of the physician in determining the prescribed regimen and convincing the patient to adhere to treatment is similarly critical. [19] The findings of the present study indicate that most healthcare providers usually offer advice regarding lifestyle changes initially, but desist over time, as recommendation rates regarding all measures of risk management beyond medication, smoking, and physical exercise declined significantly during follow-up. Hence, CV risk management strategies practiced by clinicians during 9-month follow-up seemed very effective in terms of risk reduction associated with high patient compliance. emia in almost half the study population via strategies applied within 9 months is promising.
Consideration not only of BP elevation, but also of dyslipidemia, metabolic syndrome, and metabolic disturbances (such as type 2 diabetes mellitus) by clinicians involved in day-to-day care of patients is an important step toward enhanced CV-risk reduction and treatment of hypertension in its broadest sense. [9, 25] As CVD has been the leading cause of death in essentially developed nations for more than 5 decades, anyone who successfully operates a ''better mousetrap'' to address this burden should rightfully receive admiration from the scientific community. [25] 
Study limitations
The primary strength of the present study was the inclusion of a database involving a representative sample comprising 1023 hypertensive patients from 50 centers in Turkey, likely rendering the findings widely generalizable. Nonetheless, while high-risk hypertensive patients undergoing follow-up at internal disease and cardiology clinics of tertiary centers were included, a substantial number of hypertensive patients in Turkey undergo follow-up at primary care centers. In addition, due to the non-randomized, observational design, potential selection bias and confounding factors should be considered limitations. In accordance with protocol-defined criteria, of the 1023 enrolled subjects, only 397 patients >75 years of age who were at high or very high risk were included in longitudinal analysis.
Conclusion
Based on 10-year CV risk estimates and the significant decline in percentage of patients in high-or very highrisk groups, the results of the present observational, non-interventional study indicate the efficacy of selected risk management strategies and high patient compliance during the 9-month follow-up period of the present study. Additionally, the decrease in the number of patients in higher-risk groups, particularly those with diabetic and metabolic syndromes, emphasizes the benefits of lipid and BP control. Compatible with the framework of domestic approaches such as the Total Cardiovascular Risk Management Initiative, awareness of CVD risk and implementation of prevention guidelines through direct involvement of physicians seems to play an essential role in the development of more convenient models for CV risk management.
